Back to Clinical Trials
N/AStarting soon

GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study

Sponsored by Noom Inc.

About this study

This research program includes two coordinated prospective studies (FLOURISH and THRIVE) evaluating the real-world effectiveness of Noom's digital health programs on weight, cardiometabolic biomarkers, physiological health indicators, and program engagement. FLOURISH is a 6-arm prospective cohort study comparing an Education-only control, Noom Weight, standard-dose compounded semaglutide, microdose compounded semaglutide, standard-dose tirzepatide (Noom Plus), and microdose tirzepatide (Noom Plus Microdose). THRIVE is a nested 2-arm prospective study comparing a Proactive Health program to a Noom Free Tier control. Participants complete monthly surveys, remote biomarker collection (Tasso device), connected-scale weigh-ins, and in-app biometric assessments (FaceScan, BodyScan). Microdose and Free Tier arms also use wearable fitness trackers. Primary outcomes are changes in cardiometabolic biomarkers, weight, body composition, and GLP-1 side effect profile. Total N = 2,310; 24-month duration.

FLOURISH (Functional Longitudinal Outcomes Under Repeated Intentional Small Habits) and THRIVE (Trajectories of Health, Resilience \& Integrated Vitality Evaluation) are designed to evaluate whether GLP-1 medications paired with a behavioral health digital companion delivered via the Noom application produce clinically meaningful improvements in weight, cardiometabolic biomarkers, physiological indicators, and patient-reported outcomes. All programs are commercially available Noom offerings. Research activities supplement but do not alter standard program care. Participants are recruited from active program users after program enrollment (GLP-1 programs, Noom Weight, Free Tier arms) or via an electronic recruitment platform (Education-only control). Measurement occurs at baseline and mon…

Where this study is enrolling

Who can participate

Inclusion criteria

  • ✓Speaks English
  • ✓Community-dwelling, community-living status
  • ✓Able to ambulate independently, with or without aids or devices
  • ✓Unless medically indicated, willingness to stay on current program for 12 months and participate in all study activities
  • ✓Provides informed consent for study participation
  • ✓Commitment and willingness to participate, as assessed by completion of decisional balance exercise
  • ✓Program-specific eligibility:
  • ✓Medication arms only: Meets standard of care program enrollment criteria for GLP-1 medication. Did not add other products or programs to Noom subscription.
  • ✓Noom Weight only: Individual who is not interested in medication
  • ✓Education-only Control Group: Individual who is interested in weight loss who is not currently enrolled in a structured weight loss program or medication program and does not intend to for the duration of the study Free Tier only: Willingness to use Free Tier

Exclusion criteria

  • ✕Study screener completed more than 11 days after Noom program enrollment if participating in a Noom program (GLP-1 programs, Noom Weight, and Free Tier)
  • ✕GLP-1 use in the last 24 weeks (prior to Noom program enrollment if in GLP-1 arm)
  • ✕Female who is pregnant, breast-feeding, or intends to become pregnant during the 12-month program
  • ✕Previous or planned (during the 12-month study) bariatric surgery
  • ✕Active eating disorder
  • ✕Active cancer
  • ✕Type 1 diabetes or current Insulin use
  • ✕Currently taking a medication known to cause weight gain (e.g., antipsychotics, antidepressants, diabetes medication, or corticosteroids)
  • ✕Depression screen results in a PHQ-8 score of 20 or greater.
  • ✕All medicated arms and Noom Weight arms (only):
  • ✕\- Purchased more than the base Noom program offered for participant's specific arm
  • ✕GLP-1 Medication Arms Only:
  • ✕GLP-1 agonist use is contraindicated (per program criteria) in members with:
  • ✕Personal or family history of medullary thyroid cancer
  • ✕Personal or family history of Multiple Endocrine Neoplasia Type 2 (MEN2)
  • ✕Personal history of Pancreatitis

Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.

Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.

Trial data sourced from ClinicalTrials.gov.